Abstract: The blood treatment apparatus described herein include a plurality of treatment solution reservoirs connected to a junction which feeds an output controller through an output line. The reservoirs feed the junction through one or more liquid-gas separation filters that limit or prevent air from passing. One or more of the reservoirs can typically be emptied during a treatment session without drawing air into the system.

Abstract: A system for separating the components of an incoming oil-water mixture includes two electrode sets, one set arranged to apply an electrostatic field to an oil layer residing within a separator vessel and the other set arranged to apply an electrostatic field to the interface emulsion layer residing within the separator vessel. The first set of electrodes is in communication with a high voltage power source that ranges from 1 to 60 kV; the second set of electrodes is in communication with a low voltage power source that is no greater than 5 kV. Each set of electrodes may also be in communication with a second voltage source to provide increased power to promote effective coalescence. The system may also include power electronics to produce a variable amplitude and a variable frequency voltage supply to one or both electrode sets.

Abstract: An extracorporeal system for liver dialysis comprises a filter device having hollow fibers with integrated ion-exchange particles and hydrophobic adsorbent particles in the filtrate space. The system can be used for the treatment of acute liver failure and acute-on-chronic liver failure.

Abstract: A method for regulating the growth and loss of hair via the use of compositions containing a compound selected from the group consisting of lupane triterpenes, derivatives of lupane triterpenes, derivatives of oleanane triterpenes, derivatives of ursane triterpenes, and salts and mixtures thereof.

Abstract: The invention relates to the use of substituted 2-aminothiazoles for promoting wound healing.

Abstract: Methods are provided for ameliorating various effects of UVA and UVB radiation from the sun, comprising administering compositions including an ingredient that prevents photoaging from MED and subMED radiation, such as a retinoid, certain other compounds (such as N-acetylcysteine, 2-furildioxime, and vitamin C) and optionally other MMP inhibitors such as tetracyclines and/or compounds that inhibit the P-450-mediated metabolism of retinoids such as ketoconazole and other azole compounds. In the method, the composition is applied prior to exposure to the sun; depending upon the ingredients used in the composition, application should be from 7 to 48 hours prior to exposure. Compounds that prevent erythema (skin reddening, sunburn) do not necessarily protect against UV-mediated elevation of MMP levels and activity, and similarly compounds that prevent UV-mediated elevation of MMP levels and activity are not necessarily effective against UV-induced erythema.

Abstract: The present invention describes a novel treatment for movement disorders, including tardive dyskinesia and tardive dystonia, and focal dystonias not due to neuroleptics, including blepharospasm, Meige syndrome, and occupational dystonias. The treatment of the present invention utilizes agents that act as NMDA-type glutamate receptor antagonists The invention also involves the use of an ion channel blocking agent to augment the therapeutic action of the drug treatments described. A particularly preferred ion channel blocking agent is magnesium.

Abstract: This invention relates to a stable injection paclitaxel formulation having polyoxyethylene sorbitol oleic polyester as a main solubilizer, and appears to have less toxicity and greater stability compared to polyethoxylated castor oil-containing formulation which is clinically used all over the world. The formulation includes paclitaxel 30 mg, povidone 80 mg, oxyethylene sorbitol oleate 0.5 to 2.0 ml, (oxyethylene glycol).sub.15-20 fatty acid monoester 0.5 to 2.0 ml, polyethylene glycol 1.0 ml, and anhydrous alcohol 2.0 ml. The oxyethylene sorbitol oleate is either (oxyethylene).sub.60 sorbitol tetraoleate or (oxyehtylene).sub.45 sorbitol trioleate.